Trientine - Merck/Tsumura/Bausch Health Companies

Drug Profile

Trientine - Merck/Tsumura/Bausch Health Companies

Alternative Names: Cuprid; Metalite; MK 681; Syprine; Tecza; Teta; TJA 250; Trien; Triestine

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tsumura
  • Developer Bausch Health Companies; Merck & Co; Tsumura
  • Class Ethylenediamines; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatolenticular degeneration

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 03 Mar 2014 Valeant and Kadmon Pharmaceuticals agree to co-promote Syprine® in USA for Wilson's disease
  • 01 Jan 2011 Launched for Wilson's disease in Asia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top